David Barrett Laboratory
Led by David M. Barrett, MD, PhD, researchers in the Barrett Laboratory are evaluating innovative immunotherapies, such as of Chimeric Antigen Receptor (CAR) T cells, to treat children with hematologic cancers and pediatric tumors. The long-term goal of the research conducted in this laboratory is to develop and clinically evaluate new immunotherapies for pediatric cancers and tumors that are more effective, less toxic and produce fewer side effects than existing cancer treatments.
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. 2017 Jul;19(7):867-880. doi: 10.1016/j.jcyt.2017.04.001. Epub 2017 May 11. PMID: 28506444
Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, Barrett DM.
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29. PMID: 27571406
Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053. PMID: 27632680
Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT.